10
February 2022
First Patient Dosed in Phase III Registration Study of KN046 Combined with Chemotherapy for the First Line Treatment of Advanced Pancreatic Cancer
we look forward to confirming the efficacy and safety of KN046 in advanced pancreatic cancer, bringing better treatment options to patients and improving the long-term survival.